Administration of a glycoprotein IIb/IIIa receptor blocker with a thienopyridine derivative does not increase the risk of thrombocytopenia

Administration of a glycoprotein IIb/IIIa receptor blocker with a thienopyridine derivative does not increase the risk of thrombocytopenia

Silver K H; Newman I; Rohr S M; Johnson J; Josephson R A

Ohio Journal of Science

2005

2005-09

The combination of aspirin, a thienopyridine derivative, and a glycoprotein IIb/IIIa receptor inhibitor has become standard therapy for patients undergoing percutaneous coronary intervention (PCI). Recent studies have shown an increased incidence of thrombocytopenia in those patients receiving a high loading dose of clopidogrel (thienopyridine) with abciximab (IIIb/IIIa receptor inhibitor) prior to coronary intervention. We reviewed the records of 504 patients who underwent PCI at a large tertiary care hospital and noted an incidence of thrombocytopenia of 4.8%, comparable to published historical controls who received abciximab without clopidogrel. In patients undergoing PCI, there was no difference in thrombocytopenia or bleeding complications between patients receiving a high or a low dose of a thienopyridine. We conclude that a high loading dose of a thienopyridine derivative prior to PCI may be administered safely and efficaciously in the setting of concomitant administration of abciximab without an undue risk of thrombocytopenia.

Aspirin; clopidogrel; coronary stent placement; Environmental Sciences & Ecology; implantation; population; therapy; ticlopidine; trial; Zoology

n/a

Journal Article

n/a

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

74-78

4

105